Business
Subscription skiing: Vail Resorts has has turned skiing into a subscription business

Subscription skiing: Vail Resorts has has turned skiing into a subscription business

Subscription skiing

The main moneymaker is selling lift passes, giving access to the mountain slopes, chairlifts and cable cars. The issue for resort owners is that sales of such passes are traditionally volatile, with demand changing on the whims of the weather. If lift pass sales dry up, so do Vail Resort's profits.

That’s why — from a financial perspective — Vail's masterstroke was the introduction of the Epic ski pass in 2008, offering access to an extensive portion of its ever-growing resort network.

That strategy locked in revenue by encouraging skiers to commit to a non-refundable pass before the season commenced. Originally costing $579, the Epic pass quickly became a game-changer for the company, with the more predictable revenue leading to more rapid expansion… and more competition. A similar offering — known as the IKON pass — was also launched by Vail’s competitor Alterra Mountain Company in 2018.

Last year the Epic pass cost $909, and was used by 72% of the resorts' skiers, generating ~$850 million in revenue. That's good for Vail Resorts, and for people who plan their skiing trips well in advance, but not great for anyone booking a last minute trip: on their website, a 2 day lift pass for 2 people next weekend (March 2nd and 3rd) is listed at $1,136.

An added benefit of the subscription model is that the predictable revenues are also helpful in securing financing from lenders, who don’t love the idea of lending to a business that can suffer if the weather is bad.

Snow shortfalls

Of course, short-term spouts of bad weather are one thing, but the industry is also grappling with more permanent challenges from climate change, as ski seasons get shorter. One study covering the 1982 to 2016 ski season revealed that it had been reduced by an average of 34 days across numerous resorts in the US. In the immediate term, snow cannons offer a temporary fix, promising to produce artificial snow that is 50 times harder than its natural counterpart and capable of lasting up to 5 weeks longer. Longer term, one strategy for resorts is to launch their summer activities, such as rafting and mountain biking, earlier in the year. A business for all seasons... and climates.

More Business

See all Business
business

Hims to stop offering copy of Wegovy pill following FDA scrutiny

Hims & Hers said it has decided to stop offering its newly launched copycat version of Novo Nordisk’s Wegovy pill, after the telehealth company drew criticism from the Food and Drug Administration. 

“Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment,” Hims wrote on X.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Hims oral semaglutide

Hims, long flying under regulators’ radar, finally strikes a nerve with its Wegovy pill copy

It’s unclear if the pill Hims is selling works or if the FDA will allow it.

$1.3M

There’s still plenty of money to be made in brainrot. The top 1,000 Roblox creators earned an average of $1.3 million in 2025 — up 50% from the year prior — according to CEO Dave Baszucki on the company’s fourth-quarter earnings call.

Roblox paid out $1.5 billion to creators last year, meaning its top 1,000 creators took home about 87% of the total pool.

Like other creator economy giants, Roblox rewards its biggest creators for their contributions to user engagement. Creator-made titles like “Grow a Garden” and “Steal a Brainrot” substantially boosted playing time over the course of the year. In September, the company increased its developer exchange rate, or the ratio of in-game currency to cash payout, by 8.5%.

Texas Governor Abbott And Google Make Economic Development Announcement In Midlothian

Alphabet could buy some pretty huge businesses with the amount of money it plans to spend this year

AI outlays have gone full nut-nut. Even Google, one of the most capital-efficient businesses of all time in its heyday, is spending like there’s no tomorrow.

Tom Jones2/6/26

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.